Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Deutetrabenazine (Primary)
- Indications Drug-induced dyskinesia
- Focus Registrational; Therapeutic Use
- Acronyms ARM-TD
- Sponsors Auspex Pharmaceuticals
- 27 Apr 2021 According to a Teva Pharmaceuticals media release, data from the study will be presented at the upcoming 2021 American Psychiatric Association (APA) Annual Meeting.
- 15 Apr 2021 According to a Teva Pharmaceutical Industries media release, results of an analysis assessing safety by comparing the incidence of adverse events with AUSTEDO versus placebo in two pivotal studies (ARM-TD and AIM-TD) and through week 15 of an open-label extension study (RIM-TD), will be presented at the upcoming 2021 American Academy of Neurology (AAN) Virtual Annual Meeting.
- 01 May 2020 Results (N=758), an analysis of data from two RCTs and one OLE assessing the short- and long-term effects of deutetrabenazine treatment on weight and metabolic parameters in individuals treated for tardive dyskinesia, presented at the 72nd Annual Meeting of the American Academy of Neurology